Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。